肿瘤细胞治疗研究
英文原题：Adoptive cellular therapy after hematopoietic stem cell transplantation.
使用CD19CAR-T 细胞对晚期B细胞恶性肿瘤进行有效细胞治疗，引发了移植后给予过继性细胞治疗（ACT）是否能减少复发并改善生存的问题。
使用CD19CAR-T 细胞进行有效细胞治疗以治疗晚期B细胞恶性肿瘤，提出了移植后给予过继性细胞治疗（ACT）是否能减少复发并改善生存的问题。此外，若干早期临床研究已显示，移植后给予肿瘤相关抗原特异性T细胞和NK 细胞对高风险患者具有潜在有益作用，旨在减少复发并可能改善生存。在本文中，我们对移植后ACT进行了深入综述，其有可能显著提高该操作的疗效并彻底改变这一领域。
Effective cellular therapy using CD19 chimeric antigen receptor T-cells for the treatment of advanced B-cell malignancies raises the question of whether the administration of adoptive cellular therapy (ACT) posttransplant could reduce relapse and improve survival. Moreover, several early phase clinical studies have shown the potential beneficial effects of administration of tumor-associated antigen-specific T-cells and natural killer cells posttransplant for high-risk patients, aiming to decrease relapse and possibly improve survival. In this article, we present an in-depth review of ACT after transplantation, which has the potential to significantly improve the efficacy of this procedure and revolutionize this field.
MEMBER ACCOUNT
登录成功会直接打开下一页。
